Respiratory Today—June 26, 2026

This week’s Respiratory Research update highlights regulatory progress, advancing clinical development, AI-enabled diagnosis initiatives, financing activity, and continued momentum across respiratory and pulmonary disease innovation.

In Today’s Newsletter

Dive deeper

💊 Zelicapavir advances toward registrational RSV study [1] [US • 18 Jun 2026]

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-advancement-its-zelicapavir
Context: Enanta Pharmaceuticals plans a randomized, double-blind, placebo-controlled Phase 2b/3 RSV trial in high-risk adult outpatients.
Key point: Adult Phase 2b/3 start is planned for 4Q 2026, and a pediatric Phase 2b trial is planned for 3Q 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 GRI-0621 gains FDA Orphan Drug Designation in IPF [2] [US • 18 Jun 2026]

https://gribio.com/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathic-pulmonary-fibrosis/
Context: GRI-0621 (tazarotene) is an oral RARβ/γ-selective investigational therapy for idiopathic pulmonary fibrosis.
Key point: FDA granted Orphan Drug Designation, which may provide benefits including potential seven-year US market exclusivity upon approval.
Implication: May influence prescriber choice and payer reviews pending full data.

🦠 XOCOVA pediatric COVID-19 dosing approved in Japan [3] [Japan • 19 Jun 2026]

https://www.shionogi.com/global/en/news/2026/06/20260619.html
Context: Shionogi’s XOCOVA (ensitrelvir) is an oral anti-SARS-CoV-2 main protease inhibitor.
Key point: Japan approved dosing for pediatric patients aged 6 to under 12 years who weigh at least 20 kg, plus smaller 25 mg tablets.
Implication: May expand screening, initiation, and follow-up at scale.

🌬️ KIT2014 completes first-in-human inhaled-peptide study [4] [Italy • 19 Jun 2025]

https://kitherbiotech.com/kither-biotech-successfully-completes-phase-1-clinical-trial-of-kit2014-a-novel-inhaled-peptide-therapy-for-respiratory-diseases/
Context: Kither Biotech studied KIT2014, an inhaled peptide therapy, in 56 healthy participants.
Key point: The Phase 1 study found KIT2014 was safe and well tolerated across evaluated dose levels, with no measurable systemic exposure reported.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 Pangaea Data and Sanofi target AATD detection with AI [5] [US • 22 Jun 2026]

https://www.pangaeadata.ai/2026/06/22/pangaea-data-enters-collaboration-with-sanofi-to-improve-detection-of-aatd-through-ai-driven-clinical-decision-support/
Context: Pangaea Data will configure and deploy its guideline-configured AI platform with Sanofi support.
Key point: The collaboration aims to identify patients who may meet criteria for alpha-1 antitrypsin deficiency evaluation using EHR data.
Implication: May expand screening, initiation, and follow-up at scale.

🛡️ NorthLinks Bio launches around broad-spectrum respiratory antivirals [6] [US • 23 Jun 2026]

https://www.prnewswire.com/news-releases/northlinks-bio-launches-with-34-million-financing-to-advance-broad-spectrum-respiratory-antiviral-platform-302807601.html
Context: NorthLinks Bio launched after Pneumagen reorganized into a US-based company with research operations in St Andrews, Scotland.
Key point: RA Capital Management provided $34 million to advance HEX17, an intranasal prophylactic antiviral, toward Phase 2b readiness.
Implication: Signals pipeline investment and modality expansion.

❤️ CalciMedica funds pulmonary-hypertension strategy [7] [US • 24 Jun 2026]

https://ir.calcimedica.com/news-releases/news-release-details/calcimedica-announces-private-placement-financing-approximately
Context: CalciMedica is developing CRAC channel inhibitors Auxora (zegocractin) and CM5480 for inflammatory and cardiopulmonary diseases.
Key point: The company announced private placement financing for up to about $49 million to support a pulmonary-hypertension strategy.
Implication: Signals pipeline investment and modality expansion.

Why it matters

Respiratory antiviral pipelines are moving from treatment toward prevention, with Enanta’s RSV program and NorthLinks Bio’s HEX17 prophylaxis.
Pulmonary and fibrotic disease activity remains broad, spanning IPF, PAH, AATD, COPD, NCFB, and cystic fibrosis.
AI-enabled clinical decision support is being positioned as an access and diagnosis tool in rare respiratory disease.
Multiple companies are funding or advancing earlier-stage respiratory assets, with 2027 data or regulatory milestones repeatedly flagged.

📚 See the full Respiratory archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Respiratory news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Enanta Pharmaceuticals advancing in RSV?

Enanta is advancing zelicapavir into a registrational Phase 2b/3 RSV trial in high-risk adults and a separate pediatric Phase 2b trial. Topline data for both are expected in 2027. [1]

What did FDA grant to GRI Bio’s GRI-0621?

FDA granted Orphan Drug Designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis. The designation may provide development and commercialization benefits if the product is approved. [2]

What changed for Shionogi’s XOCOVA in Japan?

Japan approved pediatric dosage and administration for XOCOVA in children aged 6 to under 12 years who weigh at least 20 kg. New 25 mg tablets were also approved. [3]

What is KIT2014 from Kither Biotech?

KIT2014 is an inhaled peptide therapy designed for respiratory diseases including COPD, non-CF bronchiectasis, and cystic fibrosis. Phase 1 data were in healthy participants, not patients. [4]

How will Pangaea Data and Sanofi use AI in AATD?

Pangaea will deploy a guideline-configured AI platform to help health systems identify patients who may meet criteria for AATD evaluation using existing EHR information. [5]

What will CalciMedica’s financing support?

CalciMedica plans to fund a Phase 1b proof-of-concept study of Auxora in PAH and IND-enabling work for oral CRAC channel inhibitor CM5480. [7]

Entities / Keywords

Enanta Pharmaceuticals, zelicapavir, RSV, respiratory syncytial virus, RiiQ, RESOLVE-P, Penta Foundation, AMS-PHPT Research Unit
GRI Bio, GRI-0621, tazarotene, idiopathic pulmonary fibrosis, IPF, Orphan Drug Designation, RARβ/γ
Shionogi, XOCOVA, ensitrelvir, COVID-19, SARS-CoV-2, pediatric dosing, Japan
Kither Biotech, KIT2014, inhaled peptide therapy, COPD, non-CF bronchiectasis, NCFB, cystic fibrosis, CF, PDE3/4, cAMP
Pangaea Data, Sanofi, alpha-1 antitrypsin deficiency, AATD, EHR, clinical decision support, AI
NorthLinks Bio, Pneumagen, RA Capital Management, HEX17, intranasal prophylactic antiviral, glycan-targeted platform
CalciMedica, Auxora, zegocractin, CM5480, CRAC channel inhibition, pulmonary hypertension, PAH